How To Mitigate Gene Editing Program Risk Through Comprehensive Off-Target Safety Profiling And Characterization

A critical challenge for therapeutic programs using CRISPR-based editing is managing the risk of off-target effects. Understanding the impact of off-targets on your specific cell type can reduce risks and strengthen your IND submission.

In this webinar, learn how to build an off-target safety package for your IND submission and get a peek into the key data Papillon Therapeutics submitted for their Friedreich’s ataxia program. You’ll hear from Papillon Therapeutics, along with off-target safety profiling experts from SeQure DX, a MaxCyte company, on how in silico and in vitro assessments can help reduce program risk. Get a first-hand account of the data package submitted as part of an IND and gain valuable insights on strengthening your gene editing program.